Testing a new treatment for a type of progressive language disorder linked to brain degeneration.
Veri-T: A phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDP
This study is looking at how safe and helpful a new medication called Verdiperstat is for people with semantic variant primary progressive aphasia (svPPA), and if you join, you might receive either the medication or a placebo without knowing which one, to help researchers learn more about treating this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10893644 on NIH RePORTER |
What this research studies
This clinical trial investigates the safety and effectiveness of Verdiperstat, a medication aimed at treating semantic variant primary progressive aphasia (svPPA), which is often associated with frontotemporal lobar degeneration. Patients will be randomly assigned to receive either the medication or a placebo in a double-blind manner, meaning neither the patients nor the researchers will know who receives which treatment. The trial will assess how well the medication is tolerated and its potential effects on the disease. This is the first multi-site trial focused on svPPA, aiming to build a foundation for future studies in this area.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with semantic variant primary progressive aphasia.
Not a fit: Patients with other forms of dementia or those not diagnosed with svPPA may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option for patients suffering from svPPA and related conditions.
How similar studies have performed: While this specific approach is novel, there is ongoing research into treatments for related conditions that may provide insights into its potential effectiveness.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Ljubenkov, Peter Alexander — University of California, San Francisco
- Study coordinator: Ljubenkov, Peter Alexander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.